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Aim To determine the contribution of clinical trials to the 
gross domestic product (GDP) in Hungary.
Methods An anonymous survey of pharmaceutical com-
panies and clinical research organizations (CROs) was con-
ducted to estimate their clinical trial-related employment 
and revenues. Clinical trial documents at the National Insti-
tute of Pharmacy (NIP) were analyzed to estimate trial-re-
lated revenues at health care institutions and the value of 
investigational medical products (IMPs) based on avoided 
drug costs. Financial benefits were calculated as 2010 US $ 
purchasing power parity (PPP) values.
Results Clinical trials increased the revenue of Hungar-
ian health care providers by US $165.6 million. The value 
of IMPs was US $67.0 million. Clinical trial operation and 
management activities generated 900 jobs and US $166.9 
million in revenue among CROs and pharmaceutical com-
panies.
Conclusions The contribution of clinical trials to the Hun-
garian GDP in 2010 amounted to 0.2%. Participation in in-
ternational clinical trials may result in health, financial, and 
intangible benefits that contribute to the sustainability of 
health care systems, especially in countries with severe re-
source constraints. Although a conservative approach was 
employed to estimate the economic benefits of clinical tri-
als, further research is necessary to improve the generaliz-
ability of our findings.
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Active participation in international clinical trials may pro-
vide health benefits to patients and financial and profes-
sional benefits to health care providers. In lower income 
economies, such as those in Central-Eastern Europe 
(CEE), the relative benefits of clinical trials are even great-
er than in the high income countries of Western Europe 
and North America. Consequently, the contribution of 
emerging markets to international clinical trials is grow-
ing substantially (1). This phenomenon is especially visible 
in CEE, where the number of clinical trials has increased 
significantly over the past 15 years and is expected to in-
crease even further in the near future (2). In CEE, interna-
tional clinical trials offer opportunities for site personnel 
to improve their professional networking and be remu-
nerated on higher-than average income level. For health 
care institutions with substantial budget constraints, tri-
al-related payments can represent an important source 
of liquid cash. A supportive attitude of hospital manage-
ment toward clinical trial activities, in terms of providing 
better working environment or increased remuneration, 
may help to prevent the migration of qualified profes-
sional staff to higher income countries. In CEE countries, 
the health status of the population is worse than in higher 
income Western European countries (3) and the accessi-
bility of new medicines is relatively limited (4). Therefore, 
through clinical trials, CEE patients can obtain access to 
standardized modern health care services, technologies, 
and investigational drugs without waiting lists or co-pay-
ments. However, investigational medical products (IMPs) 
may represent considerable health risks for patients.
The societal gain associated with clinical trials is multifacto-
rial. Clinical trials contribute to the evolution of evidence-
based medicine. They systematically investigate side ef-
fects and health outcomes not only for IMPs but also for 
the control treatment arms. Therefore, safety information, 
even about marketed therapies, is captured and no public 
investment is necessary.
The most tangible benefit may be the financial impact, 
including the contribution of trials to the revenues of 
health care providers and clinical research organizations 
(CROs). However, there are also indirect benefits, such as 
avoided health care expenses due to the free delivery of 
IMPs and services.
Few scientific publications have addressed the financial 
benefits of clinical trials. These publications examined 
avoided drug costs and additional revenues primarily from 
the viewpoint of health care institutions (5-9). There is also 
one Polish study on the national economic impact of clini-
cal trials, but the approach was not comprehensive enough 
to capture all direct and indirect financial benefits (10).
Hungary currently has a favorable position for implemen-
tation of clinical trials (11). It has high-level professional-
ism at investigational centers, rapid regulatory and ethical 
endorsements of applications, complex but manageable 
contracting processes at clinical sites, sufficient contribu-
tions to patient recruitment, and high Good Clinical Prac-
tice (GCP) quality according to Food and Drug Adminis-
tration (FDA) inspections (12). However, similarly to other 
CEE countries, the capacity for clinical trial participation in 
Hungary has not been maximized. The aim of this study 
was to determine the contribution of clinical trials to the 
national economy in Hungary. We estimated the clinical 
trial-related revenues of CROs, investigators, and health 
care institutions and the financial benefits of avoided drug 
costs due to IMPs as the percentage of the gross domestic 
product (GDP).
MethodS
The economic impact of clinical trials was measured from 
several different perspectives. In 2009, the Hungarian Clini-
cal Trial Management Society (CTMS) and the International 
Society for Pharmacoeconomics and Outcomes Research 
Hungary Chapter (ISPOR HCh) (13) obtained information 
about clinical trial-related revenues among health care in-
stitutions and CROs. In 2012, the ISPOR HCh collected addi-
tional information about the value of investigational drugs 
in clinical trials.
In the first step, to estimate the operational costs and the 
number of clinical research associates and other medical 
professionals involved in clinical trial activities in 2008, the 
CTMS conducted an anonymous survey among CRO man-
agers with operations in Hungary and medical directors 
at research-based pharmaceutical companies. The ques-
tionnaire was mailed three times to 65 companies, and 12 
questionnaires with a full set of data were returned. The 
aggregate survey results were assumed to be proportional 
to the total.
Information on clinical trial-related revenues and employ-
ment was validated and consolidated based on the annual 
balance sheets of Hungarian CROs for the 2008 fiscal year. 
In Hungary, public and private companies are obliged to 
provide annual financial data, and the Court of Regis-
tration makes these reports publicly available.
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In the second step, after having signed the National In-
stitute of Pharmacy (NIP) confidentiality agreement, two 
health economists from the ISPOR HCh reviewed the mas-
ter files of clinical trials that were approved in 2008. The 
NIP approves and controls clinical trials in Hungary and ar-
chives master files of all interventional clinical trials, includ-
ing information on trial budget estimates. The researchers 
assessed a randomly selected sample of clinical trial master 
files that were submitted to the NIP for approval. They cal-
culated the total clinical site-related budgets of the clinical 
trials, including investigator fees and institutional costs. In 
total, 313 clinical trial applications were approved. Of 59 
randomly selected studies, 9 files were excluded because 
of insufficient information on the site-related budget. The 
50 remaining trials were representative of the overall al-
location of studies in different clinical trial phases (χ2 test 
P = 0.6) (Table 1).
As no information was available on the allocation of trial 
budgets by calendar year, we assumed that the clinical trial 
revenues of health care providers before a given calendar 
year were equal to their estimated revenues in subsequent 
years. This assumption was supported by the fact that the 
number of clinical trials in Hungary remained relatively 
constant from 2006-2011 (11).
Financial figures from 2008 were converted to 2010 Hun-
garian Forint (HUF) values using the consumer price indi-
ces for 2009 and 2010 (4.2% and 4.9%, respectively). The 
results in HUF were converted into US $ using the GDP-
specific purchasing power parity (PPP) exchange rate in 
2010 (US $1 = HUF 130.12).
The third step was to estimate the indirect value of IMPs 
based on avoided drug costs for patients treated in clini-
cal trials. All phase II-IV trials that were licensed in Hungary 
in 2010 were selected. Phase I and bioequivalence studies 
were excluded because the participants are healthy vol-
unteers without a need for treatment. After signing the 
confidentiality disclosure agreement, a health economist 
retrieved information from the clinical trial master files at 
the NIP from the clinical studies approved in 2010, includ-
ing the European Clinical Trials database (EudraCT) num-
ber, detailed characteristics of the investigational com-
pound and its comparator, the dosages of IMPs that were 
provided free of charge to study participants, and the full 
study protocol. From the EudraCT database, the following 
additional information was retrieved by the NIP experts 
(only authorized individuals are allowed to retrieve data 
from this international database): clinical trial authoriza-
tion date, planned number of study participants in Hun-
gary, and Medical Dictionary for Regulatory Activities 
(MedDRA) categories for the therapeutic area. The value 
of the investigational compounds was conservatively es-
timated based on the public price of the study compara-
tor drug or a similar marketed product in the same ATC 
group or therapeutic area. The price was obtained from 
the drug list of the Hungarian National Health Insurance 
Fund (NHIF). In the three cases in which the Hungarian 
price for a first-in-class IMP or comparator was not avail-
able, German drug prices listed on www.medizinfuchs.de 
were used. The value of rescue medications was assumed 
to be zero because their use depends on IMPs and not 
on routine medical care. No additional technological costs 
were included in the value of IMPs (eg, additional diagnos-
tics). Because the number of clinical trials and the propor-
tions of different trial phases in Hungary had been con-
stant in the years before the study, we assumed that the 
value of IMPs from clinical trials approved before a given 
calendar year was equal to the estimated value of IMPs in 
the subsequent years. In 2010, 262 phase II-IV clinical trial 
applications were approved. Fourteen clinical trials were 
excluded due to incomplete data. Therefore, the value of 
IMPs was estimated based on an analysis of 248 clinical 
trial master files.
The clinical trial master files contained information only on 
the planned number of patients. Actual recruitment is usu-
ally lower than the planned number due to competitive 
recruitment among countries. As the actual number of re-
cruited patients was not known, 6 senior managers at dif-
ferent CROs were interviewed. Based on their consensus 





Proportion of assessed 
trials relative to the total (%)
Phase I and bioequivalence  38  6 15.8
Phase II  94 11 11.7
Phase III 153 29 19.0
Phase IV  28  4 14.3
Total 313 50 16.0
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statement, the ratio of planned to actual recruitment was 
assumed to be 80%. Furthermore, the assumption was that 
15% of the screened patients would drop out before treat-
ment allocation and an additional 15% would drop out at 
the mid-point of the study.
The financial benefits of the clinical trials were calculated as 
HUF 2010 values and converted into US $ 2010 PPP values. 
Finally, the total financial value of the clinical trial-related 
benefits was compared with the Hungarian GDP in 2010.
ReSuLtS
Based on the CTMS survey and data from the annual bal-
ance sheets of CROs, approximately 900 professionals, 
or 1 out of every 4350 Hungarian employees, worked in 
clinical trial-related functions at CROs and pharmaceutical 
companies. Based on data from the CTMS survey, the total 
value of trial management activities was 166.9 million in 
2010 US $. This amount included the gross income of clin-
ical trial professionals at pharmaceutical companies and 
CROs and other operational costs, such as traveling, office 
and storage costs, communication and IT costs, and legal 
and financial counseling expenses, but excluded spend-
ing at clinical sites.
According to data from the NIP, the annual revenue of 
health care professionals and their institutions at clinical 
sites was 165.6 million in 2010 US $ (Table 2), which rep-
resented an additional 2.84% of revenues to NHIF-funded 
traditional health care services. A major proportion of clini-
cal site-related revenues represented a personal income 
source for physicians and nurses.
Significant savings were generated from avoided drug 
costs for clinical trial participants. The estimated annual 
financial value of IMPs in phase II-IV clinical trials was US 
$67.0 million, which was equal to 2.52% of the NHIF phar-
maceutical budget. Phase III trials accounted to 65% of the 
total amount, whereas phase II and phase IV trials account-
ed for 15% and 20%, respectively. Three disease areas (neo-
plasms, diseases of the nervous system, and musculoskel-
etal diseases) represented 75% of the total value of IMPs, 
although they included only 30% of enrolled patients.
The revenues of health care providers (ie, investigators, 
hospitals) and the clinical trial industry, and the value of 
IMPs together amounted to US $399.5 million, which was 
equal to 0.2% of the GDP (Table 3).
dISCuSSIoN
Hungarian physicians and patients have been participating 
in international clinical trials for more than twenty years. 
However, the related economic benefits have never been 
assessed. The shared effort of two professional associations, 
namely, the CTMS (clinical trial managers) and ISPOR HCh 
(health economics researchers), aims to provide real-world 
economic data to government officials and politicians in 
order to obtain strategic support for and engagement with 
the implementation of international clinical studies.
The three-step survey about the financial impact of clinical 
trials was based on the best available data, but the gener-
alizability of our findings is limited due to several reasons. 
The sample size of the CTMS survey was relatively small. 
The review of annual balance sheets included CROs but ex-
cluded pharmaceutical companies, as clinical trial-related 
functions could not be separated from sales and market-
ing activities. The Directorate General of the NIP does not 
collect information on the number of patients who com-
tAbLe 2. Site-related budgets of clinical trials in hungary ac-
cording to the National Institute of Pharmacy documentation
total budget of approved clinical trials in 
2008 (millions, 2010 National Institute of 
Pharmacy purchasing power parity)
Phase I and  
bioequivalence
  4.9
Phase II  39.7
Phase III 114.2
Phase IV   6.8
Total 165.6
tAbLe 3. Contribution of clinical trials to the hungarian economy
Monetary value (millions, 2010 




Revenues of clinical research organizations and pharmaceutical  
companies (excluding expenditures at research sites)
166.9 0.082
Clinical trial revenue of health care institutions and investigators 165.6 0.081
Value of investigational medical products  67.0 0.033
Total contribution of clinical trials to the economy 399.5 0.195
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plete trials, so the 80% ratio of planned to actual patient 
recruitment and the average drop-out rate were based on 
expert opinions. However, Tufts Center also found a similar 
value of actual trial enrolment at Eastern European sites in 
153 international phase II-III clinical trials (76%) (14). Fur-
thermore, we could not capture the financial benefit re-
lated to improved health outcomes or the potential risks 
related to IMPs, or economic multiplicator effect of clinical 
trial activities. We also did not capture the revenues or costs 
related to capacity building of clinical research, including 
the implementation of GCP training for clinical site person-
nel and infrastructural development at research sites (eg, 
phase I research centers). In general, we employed a con-
servative approach to estimate the economic benefits of 
clinical trials.
In conclusion, participation in international clinical tri-
als may result in health, financial, and intangible benefits 
that contribute to the sustainability of health care systems 
with limited resources. The direct financial benefit of clini-
cal trials, in the form of the revenues of CROs and investi-
gators, contributed to the Hungarian GDP by 0.163%, and 
avoiding pharmaceutical spending represented addition-
al indirect benefits that accounted for 0.033% of the GDP. 
It is difficult to compare our findings to those from other 
countries as we are unaware of similar studies that have 
considered various aspects of clinical trial-related eco-
nomic benefits.
Individual countries can strengthen their market position 
if policymakers, relevant authorities, and management 
teams at investigational sites support the implementation 
of clinical trials (2,15). Long-term national strategies in dif-
ferent areas, including postgraduate education, stream-
lined ethical and regulatory approval of trials, infrastructur-
al development at trial sites, and the promotion of specific 
trial management skills and capacities, may improve the 
competitiveness of countries with severe health care re-
sources constraints. Additional efforts should be made to 
develop regional cooperation in CEE. Countries with simi-
lar backgrounds and geographical and economic statuses 
can learn from the successful strategies of other countries 
and eventually improve the competitiveness of the entire 
CEE region in attracting clinical trials.
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